Compositions suitable for treatment of spinal disease, disorder or condition
The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronectin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.
1. A method for treating a spine disease, disorder or condition comprising administering to a subject in need viral inactivated-plasma cryoprecipitate concentrate (VIPCC) in combination with notochordal-derived cells, wherein the VIPCC has an initial fibronectin/fibrinogen relative concentration of about 1/10 to about 1/5, with the proviso that tranexamic acid and bovine aprotinin are absent from the cryoprecipitate concentrate.
2. A method for treating a spine disease, disorder or condition selected from the group consisting of disc herniation, fissured disc, spinal stenosis, black disc, disc pain, central nervous system defect selected from a dura defect, brain and spinal cord injuries due to neurosurgery, trauma, ischemia, hypoxia, neurodegenerative disease, metabolic disorder, infectious disease, compression of the intervertebral disc, tumors and/or autoimmune disease comprising administration of viral inactivated-plasma activated cryoprecipitate concentrate in combination with notochordal-derived cells, wherein prior to activation said cryoprecipitate comprises an initial fibronectin/fibrinogen relative concentration of about 1/10 to about 1/5 and the cells, with the proviso that bovine aprotinin is absent from the cryoprecipitate concentrate.
3. The method according to claim 2 , for treating an intervertebral disc disease, disorder or condition.
4. A method for restoring the intervertebral disc height comprising administering a viral inactivated-plasma activated cryoprecipitate concentrate in combination with notochordal-derived cells, wherein prior to activation said cryoprecipitate comprises an initial fibronectin/fibrinogen relative concentration of about 1/10 to about 1/5 and the cells, with the proviso that tranexamic acid and bovine aprotinin are absent from the cryoprecipitate concentrate.
5. The method according to claim 1 , wherein the VIPCC comprises a contrast agent.
6. The method according to claim 5 , wherein the contrast agent is iodine.
7. The method according to claim 1 , for restoring the intervertebral disc height.
8. The method according to claim 1 , for preventing intervertebral disc herniation.
9. The method according to claim 1 , wherein the disease is an early stage of intervertebral degenerative disease.
10. The method according to claim 1 , wherein the VIPCC is activated and the activated VIPCC serves as a scaffold for reconstruction of injured or ruptured spinal cord.
11. The method according to claim 1 , for treating an intervertebral disc disease, disorder or condition.